Advisory board
The Centre for Doctoral Training (CDT) advisory board consists of high-level academic and industrial members and CDT alumni. Representatives from EPSRC also attend the Advisory board meetings. This board is updated via newsletter and is invited to CDT events such as Colloquia, summer schools and PhD project generation events. The board meets annually to ensure that both the vision and direction of the CDT are on target.
Advisory board staff profiles
Professor Peter Timmins (Chair of the Advisory Board)
Qualifications:
Professor Peter Timmins has a pharmacy degree and a PhD in pharmaceutical chemistry, both from the university of Bradford and is a Fellow of the Royal Pharmaceutical Society
Background:
Peter was most recently Executive Director, Drug Product Science and Technology, at Bristol-Myers Squibb, Moreton, Merseyside where he was head of the company’s UK R&D site. He also led drug delivery R&D activities for groups based both at Moreton and New Brunswick, New Jersey, USA. The research was focussed on applying technologies for the oral and parenteral delivery of small and large molecules having challenges such as poor solubility or requiring modified release, and was also involved in device development. Prior to joining the pharmaceutical industry he worked in the NHS, running a laboratory supporting a manufacturing unit.
Post-retirement from BMS, Peter has continued to pursue his research interests in the oral delivery of small molecules through visiting and advisory appointments at several UK universities.
Professor Eddie French
Qualifications:
Eddie has a BSc in Biochemistry and a PhD in transdermal drug delivery, both from the University of Bath. He is a visiting Professor in the Department of Pharmacy and Pharmacology and is associated with the Research in Medicines Design (ReMedDes) group.
Background:
Professor French is currently an independent pharmaceutical sciences consultant to the pharmaceutical and biotech sectors specialising in drug product development. He was previously a lecturer at Bath in the Department of Pharmacy and Pharmacology, before taking a career change and joining the pharmaceutical industry. He spent 17 years at the Pfizer Sandwich site, his time being split between leading the liquids formulation group, which included establishing Pfizer’s protein and peptide formulation capability, and as a director in the inhalation and devices group. He spent his last four years at Pfizer being the director of device enabled drug delivery, focussing on drug delivery systems for novel therapeutics and vaccines. During this time Eddie spent 9 months seconded to the STEM centre at the University of Nottingham as an EPSRC KT fellow focusing on drug delivery needs for tissue engineering and stem cells. Eddie has previously been the Chair of the Academy of Pharmaceutical Sciences of Great Britain.
Professor Peter Fryer
Qualifications
Peter was awarded an MEng and a PhD in Chemical engineering from the University of Cambridge and is now a Professor of Chemical Engineering at the University of Birmingham.
Background:
- Council Member, BBSRC
- Editor, "Food and Bioproducts Processing", Transactions of the Institution of Chemical Engineers Part C
- Member of the Editorial Board, "Journal of Food Engineering", Innovative Food Science and Emerging Technologies, Soft Matter
- IChemE representative, International Conference on Engineering and Food
Mr Stefan Ogrodzinski
Qualifications:
Stefan received his BSc (Hons) in Toxicology and Pharmacy from The School of Pharmacy, University of London, in 1987 and his MBA from De Montfort University in 1999.
Background:
Stefan's career has spanned the pharmaceutical industry, the healthcare sector, the voluntary sector and the educational sector, giving 25 years of sales, marketing, management and directorship experience.
In 2000, Stefan founded BioStatus and, since that time, has led the company as its CEO. As a founding Director of BioStatus, Stefan is responsible for the overall direction and strategic management of the business.
Stefan is also a Director of BioSuspensions Ltd, OncoTherics Ltd, BioTherics Ltd, BioCity Nottingham Ltd, MediCity Nottingham Ltd and Mobius Technology Ventures Ltd. He serves on a variety of Life Science commercial and research review panels and is a UKTI Catalyst Ambassador.
Dr Vanessa Loczenski Rose
Qualifications:
Vanessa received her degree in Medicinal Biotechnology (Dipl.-Ing) from the Technische Universität in Berlin (Germany) and undertook a PhD within the EPSRC/AstraZeneca Centre for Doctoral Training for Targeted Therapeutics and Formulation Science (2010-2014) at the School of Pharmacy in Nottingham.
Background:
After completion of her engineering degree in Berlin, Vanessa started working within the Biomarker Unit at Novartis’ Institutes for BioMedical Research in Horsham. She later joined the EPSRC/AstraZeneca Centre for Doctoral Training in Targeted Therapeutics and Formulation Science at the School of Pharmacy in Nottingham. On completion of her mini-projects, she started her PhD on novel phosphonium based polymers for nucleic acid delivery under supervision of Dr G. Mantovani, Dr S. Winkler, Dr S. Allen and Dr S.Puri (AstraZenca) including an international visit to Prof. DK Lee’s group at Sungkyunkwan University in South Korea. Vanessa successfully completed her doctorate in November 2014 and joined the Formulation Technology Group at Syngenta (Jealotts Hill) working as an RNA formulation technical specialist on several projects related to RNA interference.
Dr Annette Taylor
Qualifications:
Annette obtained a BSc and PhD from Physical Chemistry at the University of Leeds and was later RCUK Fellow, then Senior Lecturer, before taking a position in Chemical and Biological Engineering at the University of Sheffield in 2014.
Background:
During her time at Leeds she also held Visiting Researcher positions with collaborators in the USA. Her research involves combining chemical kinetics and mass transport with applications in materials science and biological processes.
Dr John Wahlich
Qualifications:
John received his PhD in Pharmaceutics from School of Pharmacy, University of Nottingham. He is a Member of the Academy of Pharmaceutical Sciences (MAPS), Fellow of the Royal Society of Chemistry (FRSC), and Chartered Chemist (C.Chem.).
Background:
John is the CEO of John Wahlich Associates Ltd a Pharmaceutical Sciences Consultancy organisation, where he has worked since 2000. He is also Executive Board member to the UK Association of Pharmaceutical Sciences (APSGB). John has 40 years’ experience in the Pharmaceutical industry of which 26 years were in GlaxoSmithKline R&D (and its heritage companies). In his various roles he has been responsible for managing over 150 scientific staff (PhD and degree level) on multiple sites and in multiple international locations.
Dr Rita Trindade
Qualifications:
Rita has an MPharm from the University of Lisbon, Portugal where she qualified as a Pharmacist. She undertook a research placement working on hot-melt extrusion that resulted in her thesis at the University of Bonn, Germany. She joined the CDT in Advanced Therapeutics and Nanomedicines back in 2014 where she obtained her PhD in Pharmaceutics from UCL.
Background:
Following her MPharm, she worked for nearly 2 years in Manufacturing and Quality Assurance of solid dosage forms at Generis Farmacêutica in Portugal. Rita’s PhD was on “Formulation strategies for extracellular vesicle delivery", supervised by Dr. Gareth Williams. She then worked as a UCL Research Fellow on formulation development for nerve repair. Rita is currently a Licensing Pharmaceutical Assessor at the Medicines and Healthcare products Regulatory Agency.